Fig 1: RBBP4 knockdown inhibits apoptosis of colon cancer cell lines. A: Apoptosis of SW620 cells examined by flow cytometry with the Annexin V-FITC/propidium iodide kit. The cells in the Q4 quadrant were defined as the apoptotic cells; B: Apoptosis of HCT116 cells examined by flow cytometry with the Annexin V-FITC/propidium iodide kit; C: Western blotting examination for apoptotic proteins. bP < 0.01 vs controls.
Fig 2: MiR‐1287‐5p plays a tumor suppressor role in non‐small cell lung cancer (NSCLC) cells partly by downregulating RBBP4. (a–j) A549/DDP and H1299/DDP cells were transfected with miR‐1287‐5p alone or together with RBBP4 plasmid. (a) The resistance of NSCLC cells to DDP was assessed by cell counting kit‐8 (CCK8) assay. (b–d) CCK8 assay and colony formation assay. (e and f) Transwell assay. (g) Flow cytometry. (h and i) Cell glycolytic metabolism was analyzed using a commercial glucose/lactate assay kit. (j) Western blot assay. *p < 0.05
Fig 3: RBBP4 knockdown inhibits migration and invasion of colon cancer cell lines. A: Migration and invasion of RBBP4 knockdown SW620 cells were measured by the transwell assay. Results were quantitated by counting migrating and invasive cells in five randomly chosen high-power fields for each replicate; B: Migration and invasion of RBBP4 knockdown HCT116 cells were measured by the transwell assay; C: Western blotting examination for epithelial-mesenchymal transition related proteins. bP < 0.01 vs controls.
Fig 4: Expression of RBBP4 in colon cancer cell lines and its effect on cell proliferation. A: Protein level of RBBP4 in the colon cancer cell lines quantified by western blotting; B: mRNA level of RBBP4 in the colon cancer cell lines quantified by polymerase chain reaction; C: RBBP4 siRNA efficiency verified by western blotting in SW620 and HCT116 cells; D: Cell viability was detected by the Cell Counting Kit-8 assay in HCT116 cells; E: Cell viability was detected by the Cell Counting Kit-8 assay in SW620 cells; F and G: Cell proliferation was detected by 5-ethynyl-2’-deoxyuridine assay in HCT116 cells and SW620 cells. bP < 0.01 vs controls. EdU: 5-Ethynyl-2’-deoxyuridine.
Fig 5: Effect of RBBP4 on activation of Wnt/β-catenin pathway. A: The TOPFlash experiment in SW620 cells with RBBP4 knockdown or RBBP4 overexpression; B: The TOPFlash experiment in HCT116 cells with RBBP4 knockdown or RBBP4 overexpression; C: Western blotting of the level of β-catenin in cell nucleus and cytoplasm. bP < 0.01 vs controls.
Supplier Page from Abcam for Anti-RBBP4 antibody [EPR3412] - ChIP Grade